Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1CNS 1

Conditions

Sarcoma 1Osteosarcoma 1Neuroblastoma 1Melanoma 1

Interventions

Cyclophosphamide 16Filgrastim 15Etoposide 10Carboplatin 10Peripheral Blood Stem Cell Transplantation 8Melphalan 8Magnetic Resonance Spectroscopy 7Granulocyte Colony-Stimulating Factor 7Busulfan 7Thiotepa 6Temozolomide 6Radiotherapy 6Ifosfamide 6etoposide phosphate 5X-Rays 5Topotecan 5Phantoms, Imaging 5Doxorubicin 5Cisplatin 5Vincristine 4Specimen Handling 4Nuclear Medicine Department, Hospital 4Mesna 4selpercatinib 3sargramostim 3pembrolizumab 3palbociclib 3aldesleukin 3Sirolimus 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × AP 1903 reagent × CNS × Clear all
NCT02107963 2024-05-16

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled
CNSDermatologicSarcoma

Melanoma, Neuroblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡